MA40580A - Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques - Google Patents

Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Info

Publication number
MA40580A
MA40580A MA040580A MA40580A MA40580A MA 40580 A MA40580 A MA 40580A MA 040580 A MA040580 A MA 040580A MA 40580 A MA40580 A MA 40580A MA 40580 A MA40580 A MA 40580A
Authority
MA
Morocco
Prior art keywords
integrin
antagonists
beta
alpha
treatment
Prior art date
Application number
MA040580A
Other languages
English (en)
Other versions
MA40580B1 (fr
Inventor
Niall Andrew Anderson
Matthew Howard James Campbell-Crawford
Ashley Paul Hancock
John Martin Pritchard
Joanna Mary Redmond
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA40580A publication Critical patent/MA40580A/fr
Publication of MA40580B1 publication Critical patent/MA40580B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un composé de formule (i), ce dernier étant un acide 4-(3-fluoro-3-(2-(5, 6, 7, 8-tétrahydro-l, 8-naphthyridin-2-yl) éthyl) pyrrolidin-l-yl)-3-(3-(2-méthoxyéthoxy) phényl) butanoïque, ou un sel de ce dernier.
MA40580A 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques MA40580B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417002.1A GB201417002D0 (en) 2014-09-26 2014-09-26 Novel compound
PCT/EP2015/071776 WO2016046225A1 (fr) 2014-09-26 2015-09-22 Nouveaux composés
EP15767475.5A EP3197892B1 (fr) 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Publications (2)

Publication Number Publication Date
MA40580A true MA40580A (fr) 2017-08-02
MA40580B1 MA40580B1 (fr) 2018-09-28

Family

ID=51901158

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40580A MA40580B1 (fr) 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Country Status (37)

Country Link
US (3) US9956209B2 (fr)
EP (2) EP3428167A1 (fr)
JP (1) JP6611799B2 (fr)
KR (1) KR101998000B1 (fr)
CN (1) CN107074848B (fr)
AR (1) AR101994A1 (fr)
AU (1) AU2015320858B2 (fr)
BR (1) BR112017006251A2 (fr)
CA (1) CA2962315A1 (fr)
CL (1) CL2017000705A1 (fr)
CO (1) CO2017002714A2 (fr)
CR (1) CR20170112A (fr)
CY (1) CY1121071T1 (fr)
DK (1) DK3197892T3 (fr)
DO (1) DOP2017000081A (fr)
EA (1) EA031481B1 (fr)
ES (1) ES2690748T3 (fr)
GB (1) GB201417002D0 (fr)
HR (1) HRP20181796T1 (fr)
HU (1) HUE041827T2 (fr)
IL (1) IL250592A0 (fr)
JO (1) JO3413B1 (fr)
LT (1) LT3197892T (fr)
MA (1) MA40580B1 (fr)
MX (1) MX2017003948A (fr)
PE (1) PE20170502A1 (fr)
PH (1) PH12017500361A1 (fr)
PL (1) PL3197892T3 (fr)
PT (1) PT3197892T (fr)
RS (1) RS58000B1 (fr)
SG (1) SG11201701183YA (fr)
SI (1) SI3197892T1 (fr)
SM (1) SMT201800513T1 (fr)
TW (1) TW201629056A (fr)
UA (1) UA119181C2 (fr)
UY (1) UY36314A (fr)
WO (1) WO2016046225A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604589D0 (en) * 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
PT3538525T (pt) 2016-11-08 2022-08-16 Bristol Myers Squibb Co Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina
CN110167934B (zh) 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
EP3538528B1 (fr) 2016-11-08 2020-12-23 Bristol-Myers Squibb Company Amides de pyrrole en tant qu'inhibiteurs d'intégrine alpha v
EA201991123A1 (ru) 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
AU2017359028A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Azole amides and amines as alpha V integrin inhibitors
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (fr) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
US11332498B2 (en) 2017-03-17 2022-05-17 Technische Universitat Munchen Ligands for integrin αVβ8, synthesis and uses thereof
JP7291696B2 (ja) 2017-11-07 2023-06-15 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのピロロピラジン誘導体
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用
WO2020047208A1 (fr) * 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
PT3844162T (pt) * 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
EP3843728B1 (fr) * 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
JP2022512648A (ja) * 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
US20240165195A1 (en) * 2018-10-09 2024-05-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
US11034710B2 (en) * 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9192000A3 (en) 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
EP1047425A4 (fr) 1997-12-17 2009-04-22 Merck & Co Inc Antagonistes du recepteur de l'integrine
DE60035779T2 (de) 1999-06-02 2008-04-30 Merck & Co., Inc. Alpha v integrin-rezeptor antagonisten
EP1194151A4 (fr) 1999-06-23 2003-01-15 Merck & Co Inc Antagonistes des recepteurs de l'integrine
EP1229910A4 (fr) * 1999-10-04 2003-10-01 Merck & Co Inc Antagonistes des recepteurs d'integrine
YU32502A (sh) 1999-11-08 2004-12-31 Merck & Co.Inc. Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina
US6921767B2 (en) 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
AU7793501A (en) 2000-07-26 2002-02-05 Merck & Co Inc Alpha v integrin receptor antagonists
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
AU2002246757B2 (en) 2001-01-03 2006-02-02 Merck & Co., Inc. Methods and compositions for treating periodontal disease
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
MY147019A (en) 2002-03-13 2012-10-15 Biogen Idec Inc Anti-alpha v beta 6 antibodies
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
MX2009010050A (es) 2007-03-23 2009-10-12 Amgen Inc Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
WO2011111880A1 (fr) 2010-03-08 2011-09-15 주식회사 메디젠텍 Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
EP3925959A1 (fr) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Dérivés fluorés de l'acide 3-(2-oxo-3-(3-(5,6,7,8-tétrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoïque et leurs utilisations
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
GB201417002D0 (en) 2014-11-12
IL250592A0 (en) 2017-04-30
MA40580B1 (fr) 2018-09-28
HRP20181796T1 (hr) 2018-12-28
PH12017500361B1 (en) 2017-07-17
RS58000B1 (sr) 2019-01-31
UA119181C2 (uk) 2019-05-10
HUE041827T2 (hu) 2019-05-28
AU2015320858B2 (en) 2018-10-18
UY36314A (es) 2016-04-29
JP2017528507A (ja) 2017-09-28
LT3197892T (lt) 2018-12-10
SI3197892T1 (sl) 2018-12-31
EP3428167A1 (fr) 2019-01-16
AR101994A1 (es) 2017-01-25
US9956209B2 (en) 2018-05-01
DK3197892T3 (en) 2018-11-26
CN107074848A (zh) 2017-08-18
US20180271845A1 (en) 2018-09-27
PT3197892T (pt) 2018-12-12
PH12017500361A1 (en) 2017-07-17
DOP2017000081A (es) 2017-04-30
US20170290817A1 (en) 2017-10-12
CN107074848B (zh) 2019-11-01
CY1121071T1 (el) 2019-12-11
BR112017006251A2 (pt) 2017-12-12
US20190275016A1 (en) 2019-09-12
PE20170502A1 (es) 2017-04-27
PL3197892T3 (pl) 2019-05-31
CL2017000705A1 (es) 2017-11-03
US10342783B2 (en) 2019-07-09
SMT201800513T1 (it) 2018-11-09
JP6611799B2 (ja) 2019-11-27
ES2690748T3 (es) 2018-11-22
MX2017003948A (es) 2017-06-26
SG11201701183YA (en) 2017-04-27
EA201790715A1 (ru) 2017-07-31
JO3413B1 (ar) 2019-10-20
WO2016046225A1 (fr) 2016-03-31
EA031481B1 (ru) 2019-01-31
CR20170112A (es) 2017-05-26
KR101998000B1 (ko) 2019-07-08
KR20170055489A (ko) 2017-05-19
CA2962315A1 (fr) 2016-03-31
TW201629056A (zh) 2016-08-16
EP3197892B1 (fr) 2018-09-05
EP3197892A1 (fr) 2017-08-02
AU2015320858A1 (en) 2017-03-09
CO2017002714A2 (es) 2017-06-30

Similar Documents

Publication Publication Date Title
MA40580B1 (fr) Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA35725B1 (fr) Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk
EA202091506A1 (ru) Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa
MX2016017147A (es) Compuestos de indazole substituidos como inhibidores de irak4.
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
EP3952865A4 (fr) Composés hétérocycliques en tant qu'inhibiteurs de kinase pour des utilisations thérapeutiques
PH12016501440A1 (en) Novel heterocyclic compounds
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MX378717B (es) Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble.
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
MA40302A1 (fr) Dérivés de carbazole
WO2015100092A3 (fr) Analogues 7-bêta d'orvinols
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
PE20161315A1 (es) Compuestos de pirazolona y usos de los mismos
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
GEAP202115141A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
EP4036095A4 (fr) Composés de pyrazolopyridine utiles en tant qu'inhibiteurs sélectifs de la btk kinase
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety